{"id":2539,"date":"2018-11-06T19:46:27","date_gmt":"2018-11-06T19:46:27","guid":{"rendered":"http:\/\/madhousereport.com\/?p=2539"},"modified":"2018-11-06T19:46:27","modified_gmt":"2018-11-06T19:46:27","slug":"ekos-control-unit-4-0-simplifies-treatment-blood-clots","status":"publish","type":"post","link":"https:\/\/theblogonline.com\/?p=2539","title":{"rendered":"EKOS\u2122 Control Unit 4.0 Simplifies Treatment Of Blood Clots"},"content":{"rendered":"

First commercial units are shipped to Europe<\/b><\/span><\/p>\n

LONDON–(BUSINESS WIRE<\/span><\/a><\/span>\/AETOSWire<\/span><\/a><\/span>)– BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS\u2122 CU 4.0 units have been shipped from BTG\u2019s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS\u2122 CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS\u2122 devices simultaneously.<\/span><\/p>\n

These improvements simplify bilateral treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT). Using CU 4.0, physicians can treat both pulmonary arteries and can easily monitor and manage two EKOS\u2122 devices at the same time.<\/span><\/p>\n

European patients with PEs and DVTs have already successfully been treated with EKOS\u2122 CU 4.0 during a limited release of the product.<\/span><\/p>\n

Professor Nils Kucher, Director of Clinic of Angiology at University Hospital in Zurich, Switzerland said: \u201cI\u2019ve used EKOS\u2122 therapy for over 10 years. This latest innovation of the technology is a big step for simplifying thrombosis treatment.\u201d<\/span><\/p>\n

EKOS\u2122 is the only device to have both FDA Clearance and a CE Mark [0086] for the treatment of PE. The system includes an ultrasonic device that uses acoustic pulses, which enable quick and safe dissolution of blood clots and restore blood flow in patients with PE, DVT and peripheral arterial occlusions.<\/span><\/p>\n

About BTG<\/b><\/span><\/p>\n

BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer and vascular conditions. BTG\u2019s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.<\/span><\/p>\n

EKOS is a registered trademark of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International LTD.<\/span><\/p>\n

Product availability varies by country. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Prior to use, please refer to the applicable Instructions for Use (IFU) for complete product indications, contraindications, warnings, and precautions.<\/span><\/p>\n

View source version on businesswire.com:\u00a0https:\/\/www.businesswire.com\/news\/home\/20181105006071\/en\/<\/span><\/a><\/span><\/p>\n

*Source: <\/b>AETOSWire<\/b><\/span><\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

First commercial units are shipped to Europe LONDON–(BUSINESS WIRE\/AETOSWire)– BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS\u2122 CU 4.0 units have been shipped from BTG\u2019s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS\u2122 CU 4.0 include an interactive colour […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1882,1881],"class_list":["post-2539","post","type-post","status-publish","format-standard","hentry","category-metro","tag-blood-clots","tag-ekos-control-unit-4-0"],"_links":{"self":[{"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/posts\/2539"}],"collection":[{"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/theblogonline.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2539"}],"version-history":[{"count":1,"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/posts\/2539\/revisions"}],"predecessor-version":[{"id":2540,"href":"https:\/\/theblogonline.com\/index.php?rest_route=\/wp\/v2\/posts\/2539\/revisions\/2540"}],"wp:attachment":[{"href":"https:\/\/theblogonline.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theblogonline.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theblogonline.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}